Rocket Pharmaceuticals Updates on RP-A601 Trial Progress

Rocket Pharmaceuticals ( (RCKT) ) has shared an update.

On May 15, 2025, Rocket Pharmaceuticals presented updates on their Phase 1 clinical trial of RP-A601 at the American Society of Gene and Cell Therapy Annual Meeting. The trial aims to treat plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM), a condition with no current curative treatments. The preliminary data suggests that RP-A601, an AAV gene therapy, shows promise in driving therapeutic transgene expression in cardiomyocytes, potentially altering disease progression and offering a new treatment avenue for PKP2-ACM patients.

The most recent analyst rating on (RCKT) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.

Spark’s Take on RCKT Stock

According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.

Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.

To see Spark’s full report on RCKT stock, click here.

More about Rocket Pharmaceuticals

Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare and devastating diseases. Their primary products include treatments for conditions such as Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Danon Disease. The company aims to leverage its gene therapy technologies to address unmet medical needs in these areas.

Average Trading Volume: 2,695,955

Technical Sentiment Signal: Sell

Current Market Cap: $712.7M

Learn more about RCKT stock on TipRanks’ Stock Analysis page.